PER 4.65% 9.0¢ percheron therapeutics limited

atl1102 a clear winner, page-5

  1. 1,496 Posts.
    In the ann dated 20 Sept 2011 on ATL1102, ANP stated the comparison value of another Stem Cell Mobilisation therapy, Mobobil:

    "One such complimentary therapy, Mozobil, has been approved for use in combination with the main agent G-CSF. First marketed in 2009, MozobilTM sales in 2010 were ~US$100Mill with peak sales potential estimated at US$350Mill per annum."
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
9.0¢
Change
0.004(4.65%)
Mkt cap ! $81.13M
Open High Low Value Volume
8.6¢ 9.1¢ 8.5¢ $181.6K 2.049M

Buyers (Bids)

No. Vol. Price($)
1 10344 8.7¢
 

Sellers (Offers)

Price($) Vol. No.
9.0¢ 64275 1
View Market Depth
Last trade - 16.10pm 13/09/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.